8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Variant-aware saturating mutagenesis using multiple Cas9 nucleases identifies regulatory elements at trait-associated loci

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cas9-mediated, high-throughput, saturating in situ mutagenesis permits fine-mapping of function across genomic segments. Disease- and trait-associated variants from genome-wide association studies largely cluster in regulatory DNA. Here we demonstrate the use of multiple designer nucleases and variant-aware library design to interrogate trait-associated regulatory DNA at high resolution. We developed a computational tool for the creation of saturating mutagenesis libraries with single or combinatorial nucleases with incorporation of variants. We applied this methodology to the HBS1L-MYB intergenic region, a locus associated with red blood cell traits, including fetal hemoglobin levels. This approach identified putative regulatory elements that control MYB expression. Analysis of genomic copy number highlighted potential false positive regions, which emphasizes the importance of off-target analysis in design of saturating mutagenesis experiments. Taken together, these data establish a widely applicable high-throughput and high-resolution methodology to reliably identify minimal functional sequences within large regions of disease- and trait-associated DNA.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.

          Genetic screens are powerful tools for identifying genes responsible for diverse phenotypes. Here we describe a genome-wide CRISPR/Cas9-mediated loss-of-function screen in tumor growth and metastasis. We mutagenized a non-metastatic mouse cancer cell line using a genome-scale library with 67,405 single-guide RNAs (sgRNAs). The mutant cell pool rapidly generates metastases when transplanted into immunocompromised mice. Enriched sgRNAs in lung metastases and late-stage primary tumors were found to target a small set of genes, suggesting that specific loss-of-function mutations drive tumor growth and metastasis. Individual sgRNAs and a small pool of 624 sgRNAs targeting the top-scoring genes from the primary screen dramatically accelerate metastasis. In all of these experiments, the effect of mutations on primary tumor growth positively correlates with the development of metastases. Our study demonstrates Cas9-based screening as a robust method to systematically assay gene phenotypes in cancer evolution in vivo.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis

            Summary Enhancers, critical determinants of cellular identity, are commonly identified by correlative chromatin marks and gain-of-function potential, though only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously we identified an erythroid enhancer of BCL11A, subject to common genetic variation associated with fetal hemoglobin (HbF) level, whose mouse ortholog is necessary for erythroid BCL11A expression. Here we develop pooled CRISPR-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for HbF reinduction. The detailed enhancer map will inform therapeutic genome editing. The screening approach described here is generally applicable to functional interrogation of noncoding genomic elements.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing

              The Cas9 protein from the Streptococcus pyogenes CRISPR-Cas immune system has been adapted for both RNA-guided genome editing and gene regulation in a variety of organisms, but can mediate only a single activity at a time within any given cell. Here we characterize a set of fully orthogonal Cas9 proteins and demonstrate their ability to mediate simultaneous and independently targeted gene regulation and editing in bacteria and in human cells. We find that Cas9 orthologs display consistent patterns in their recognition of target sequences and identify a highly targetable protein from Neisseria meningitidis. Our results provide a basal set of orthogonal RNA-guided proteins for controlling biological systems and establish a general methodology for characterizing additional proteins and adapting them to eukaryotic cells.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                31 January 2017
                20 February 2017
                April 2017
                20 August 2017
                : 49
                : 4
                : 625-634
                Affiliations
                [1 ]Division of Hematology/Oncology, Boston Children’s Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts 02115, USA
                [2 ]Montreal Heart Institute, Montréal, Québec H1T 1C8, Canada, and Université de Montréal, Montréal, Québec H3T 1J4, Canada
                [3 ]Department of Molecular Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
                [4 ]Red Cell Genetic Disease Unit, Hôpital Henri-Mondor, Assistance Publique–Hôpitaux de Paris (AP-HP), UPeC, IMRB - U955 - Equipe n°2, Créteil, France
                [5 ]Department of Laboratory Medicine, Boston Children’s Hospital, Boston, Massachusetts 02115, USA
                [6 ]Department of Medicine, Sickle Cell Center, Augusta University, Augusta, Georgia, USA
                [7 ]The Caribbean Institute for Health Research, University of the West Indies, Mona, Kingston 7, Jamaica
                [8 ]Department of Research and Development, Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan
                [9 ]Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan
                [10 ]Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
                [11 ]Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA
                [12 ]Howard Hughes Medical Institute, Boston Massachusetts 02115, USA
                Author notes
                Correspondence should be addressed to S.H.O. ( Stuart_Orkin@ 123456dfci.harvard.edu ) or D.E.B. ( Daniel.Bauer@ 123456childrens.harvard.edu )
                [*]

                These authors jointly supervised this work.

                Article
                NIHMS846978
                10.1038/ng.3793
                5374001
                28218758
                eb5ea9ee-23fd-42dc-8fac-85fcf211711d

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article